Healthcare Triangle Sets October 23 Vote on 1:25 Reverse Split and $100M Dilutive Issuance to Avoid Nasdaq Delisting
HCTI is trading near its 52-week low of $0.41 (4.8% above the low) on light trading volume (0.1× avg).
Summary
Healthcare Triangle's definitive proxy sets an October 23 special meeting to vote on a 1:25 reverse split and a $100M dilutive issuance authorization, both aimed at avoiding Nasdaq delisting after the company received a delisting determination on October 2.
Key Events · Corporate Governance and Compliance · HCTI
-
Reverse Split Vote Set for October 23
Shareholders will vote on a reverse split ranging from 1:2 to 1:25, with the exact ratio to be determined by the Board. The company received a Nasdaq Staff Delisting Determination on October 2 for failing to maintain a $1.00 minimum bid price.
-
$100M Dilutive Issuance Authorization
The 20% Issuance Proposal authorizes up to 250 million shares of common stock plus 250 million warrant shares at discounts of up to 80% to market, with a maximum issuance amount of $100 million and a closing deadline of January 23, 2027.
-
Massive Dilution Risk
With only 17.7 million shares outstanding, the authorized 250 million shares represent over 14x the current share count. The 80% maximum discount to market would price shares at approximately $0.086 based on the current $0.43 price.
-
Nasdaq Delisting Pressure
The company received a Staff Delisting Determination on October 2, 2026. The reverse split is designed to increase the per-share price above $1.00 to regain compliance, but Nasdaq rules limit additional compliance periods if a reverse split fails.
Analysis · HCTI · Technology
Healthcare Triangle is asking shareholders to approve a reverse split of up to 1-for-25 and a $100 million dilutive issuance authorization at a special meeting on October 23, 2026. The company received a Nasdaq Staff Delisting Determination on October 2 for failing to maintain a $1.00 minimum bid price, and the reverse split is the primary mechanism to regain compliance. The 20% Issuance Proposal authorizes up to 250 million shares of common stock plus 250 million warrant shares at discounts of up to 80% to market, which would massively dilute existing holders. The company had only $1.9 million in cash as of Q2 2026 and is pursuing multiple acquisitions, so this capital raise is critical for survival but comes at severe cost to current shareholders.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 44.1% of the 299 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCTI was trading at $0.43 on NASDAQ in the Technology sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $0.41 to $188.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.